Statement of Principles concerning diabetes mellitus (Balance of Probabilities) (No. 49 of 2020)

Legal character and evidential standard. The SOP is a statutory instrument within the VEA framework. It is not a clinical guideline but a legal standard of medical causation; it identifies the specific factual and medical elements which, if established on the balance of probabilities, permit a decision‑maker to find that diabetes mellitus or death from diabetes mellitus is connected with relevant service (s 3; s 5; s 8; s 9). The evidential standard is the civil standard, balance of probabilities; the RMA states that the SOP reflects what is "more probable than not" based on sound medical‑scientific evidence (s 8).

Defined outcome and diagnostic criteria. The instrument defines diabetes mellitus for legal purposes, not merely by ICD code. It provides objective criteria: either two positive laboratory blood tests on separate days meeting specific thresholds (fasting plasma glucose ≥ 7.0 mmol/L, or 2‑hour glucose ≥ 11.1 mmol/L after 75 g glucose, or HbA1c ≥ 6.5%), or an episode of diabetic ketoacidosis or hyperosmolar hyperglycaemic state with blood glucose ≥ 11.1 mmol/L (s 7(2)(a)(i)-(ii)). Death from diabetes mellitus is included where the terminal event or condition was contributed to by the person’s diabetes (s 7(5)).

Categorisation of factors. The SOP operates by specifying a finite list of factors. These are preconditions that can establish a causal link when proven and connected to relevant service. The list is structured so that some factors apply to clinical onset, others to clinical worsening, and several apply only to particular types of diabetes (type 1, type 2, or gestational). The SOP therefore distinguishes:

• Type‑specific factors, for example pancreatic surgery and Vacor ingestion for type 1, smoking and obesity for type 2 (s 9(6), s 9(7) and s 9(21)).
• Timing and exposure windows, for example last glucocorticoid dose within 30 days of onset or worsening, immune checkpoint inhibitor or interferon within one year of onset or worsening, smoking cessation windows of 15 years for type 2 onset/worsening (s 9(3), s 9(6)(e), s 9(13a), s 9(7)(a), s 9(21)(a)).
• Medication and drug lists that are specified in the Schedule, for example Specified List 1 and Specified List 2, and defined glucocorticoid thresholds (Schedule 1 definitions; s 9(4), s 9(12), Schedule 1).

Interplay with other SOPs. Where a listed factor refers to an injury or disease that is subject to another SOP, that other SOP’s factors apply (s 11). That mechanism creates a legal network of SOPs rather than isolated lists; a factor that is itself a separate compensable injury will be assessed by its own SOP as part of the causal chain.

Relationship to service. A factor alone is insufficient. Section 10 requires that any factor relied upon must be related to the person’s relevant service. Subsection 10(2) further clarifies that factors set out in subsections 9(9) to 9(23) apply only to material contribution to, or aggravation of, diabetes mellitus where the disease existed before or during relevant service but did not arise out of that service. In short, the SOP separates connection due to factors that arise in service from material contribution or aggravation of pre‑existing disease.

Administrative application. Decision‑makers apply the SOP when determining whether diabetes mellitus or death from diabetes is related to relevant service for the purposes of VEA and MRCA claims (s 5). The SOP is therefore both prescriptive and limiting: it prescribes which factors, if proven and related to service, meet the RMA’s medical view, and it limits service connection findings to those factual scenarios.

Definitions shaping application. The Schedule contains tightly framed definitions that matter for evidentiary thresholds: the calculation of pack‑years and the amended definition of one pack‑year, the numeric BMI and waist circumference cut‑offs for overweight/obese, the MET threshold for physical activity, the concentrations and durations for arsenic exposure, the detailed glucocorticoid dosage schedules and equivalent inhaled glucocorticoid thresholds, lists of drugs, specified endocrine disorders, and what constitutes terminal events (Schedule 1). These definitions convert clinical or epidemiological concepts into legally operational elements.

Primary groups affected. The instrument applies to claimants who are veterans or members of the Forces bringing claims under the VEA or MRCA provisions identified in s 5. That means persons with relevant service as defined in the Schedule , eligible war service or defence service under the VEA (excluding operational or hazardous service and British nuclear test defence service) and peacetime service under the MRCA , and their legal representatives, medical advisers and decision‑makers in DVA processes (s 5; Schedule 1 definition of relevant service). It also affects surviving dependants or estates when the claimed condition is death from diabetes mellitus (s 7(5)).

Medical professionals and record keepers. Treating clinicians, hospitals and allied health professionals who diagnose, treat or manage diabetes, endocrine disorders, transplants, psychiatric disorders, infections, or relevant exposures will be affected because the SOP requires contemporaneous clinical evidence mapped to the criteria in the instrument. That includes general practitioners who must supply documented fasting glucose, glucose tolerance or HbA1c results; specialists who must document pancreatic surgery, pathological pancreatic conditions, transplants, or psychiatric diagnoses; and pharmacists or prescribing clinicians whose records will be used to verify exposure to listed drugs, glucocorticoid dosages and immune checkpoint inhibitor or interferon therapy (s 7(2); s 9; Schedule 1).

Policy and administrative actors. DVA assessors, RMA advisors, MRCA administrators, and reviewers engaged in merits or judicial review of entitlement decisions need to apply the SOP’s factors and definitions. The SOP shapes record requests, expert instructions, and the framing of medical questions asked of treating doctors or independent medical experts (s 8-11).

Third parties and public health data holders. Entities with exposure data , for example water authorities in arsenic exposure scenarios, employers maintaining workplace exposure or smoking records, and service medical units that administered drugs while the person was in service , will be relevant sources of evidence. The SOP’s arsenic exposure test requires water concentration and duration data or clinical evidence of chronic arsenic toxicity (Schedule 1).

Who is not covered or limited. Individuals whose exposure or disease process falls outside the SOP’s defined factors may still pursue claims, but the SOP sets the RMA’s view of what is "more probable than not." The instrument excludes impaired glucose tolerance from the definition of diabetes mellitus (s 7(2)(c)). The relevant service definition also narrows the population whose service can be linked, by excluding operational or hazardous service categories for certain VEA definitions described in Schedule 1.

Behaviours and clinical activities affected. The SOP has consequences for behaviours that are material to claims: recording smoking histories in pack‑years and noting cessation dates matters because s 9(7)(a) and s 9(21)(a) use a five pack‑year threshold and a 15‑year cessation window; documentation of second‑hand smoke exposure hours matters because of the 5,000‑hour criterion (s 9(7)(b); s 9(21)(b); Schedule 1). Similarly, clinicians and administrators must evidence the timing of glucocorticoid dosage and the exact drugs prescribed to meet the specified thresholds (s 9(3); Schedule 1).

Indirectly affected groups. Medicinal product manufacturers and oncology units may be indirectly affected because the SOP enumerates immune checkpoint inhibitors, interferons, and many commonly prescribed drugs in Specified List 1 and Specified List 2; these listings determine when particular drug exposures are legally significant in establishing a service connection (s 9(4), s 9(12); Schedule 1).

Duties under the instrument. The SOP itself does not impose duties in the form of criminal sanctions; instead, it prescribes criteria that must be applied by decision‑makers. The operative duty on decision‑makers is to apply the SOP when assessing claims under the VEA and MRCA sections identified in s 5. That means decision‑makers must determine whether the claimant has established, on the balance of probabilities, both that diabetes mellitus (as defined in s 7(2)) exists and that at least one of the enumerated factors in s 9 existed and was related to relevant service (s 5; s 7; s 8; s 9; s 10).

Duties for claimants and medical witnesses. Claimants bear the practical obligation of adducing evidence that maps to the SOP elements. They must present laboratory results, medication records, clinical diagnoses, and timeline evidence to show temporal proximity between the factor and clinical onset or worsening. For example, to rely on glucocorticoid therapy as a factor, evidence must show that doses and cumulative exposure meet the thresholds in Schedule 1 and for onset/worsening that the last dose was within the specified window (s 9(3); Schedule 1). To rely on smoking, the claimant must show a smoking history meeting the pack‑years calculation in Schedule 1. To rely on inability to obtain appropriate clinical management, the claimant must show records or contemporaneous evidence of that inability (s 9(23)).

Rights conferred or clarified. The SOP gives claimants a structured right to have claims assessed against a known set of medical criteria. If a claimant establishes a listed factor and its relationship to relevant service on the balance of probabilities, decision‑makers are guided by the RMA’s view to find a service connection for diabetes mellitus or related death, subject to legal and evidentiary assessment (s 8; s 9; s 10). Section 11 gives claimants the right to have cross‑referenced injuries or diseases assessed by their own SOPs where a listed factor refers to them; that ensures consistency between SOPs.

Administrative rights and review. The SOP is applied within the VEA and MRCA claims framework, which provides administrative avenues for review and appeal under those Acts. The instrument does not itself create or curtail those rights; it operates as the evidentiary standard decision‑makers use when exercising their statutory functions under VEA s 120B or MRCA s 339 (s 5). The SOP also clarifies that decision‑makers must account for the definitions in the Schedule when determining whether thresholds are met.

Limits and constraints. Section 10 constrains possible findings: a factor must be related to relevant service to establish a service connection. In particular, subsections 9(9) to 9(23) are confined to material contribution to or aggravation of an existing diabetes where the diabetes was suffered or contracted before or during relevant service but did not arise out of the service (s 10(2)). This structure sets a workably narrow legal test when the disease pre‑existed or was present during service.

Evidentiary boundaries. The SOP specifies the forms of evidence that will be determinative , laboratory results, documented medical events, recorded doses and drug names, duration thresholds, and objective measures such as BMI and waist circumference. These are legally relevant rights and duties for parties to a claim; evidence that does not correspond to the instrument’s elements is less likely to establish the required causal connection.

No penalties in the instrument. The Statement of Principles does not create criminal offences, civil penalties, or administrative sanctions within its text. It is an evidentiary and causation instrument used to determine entitlement to benefits under the VEA and MRCA. The SOP does not prescribe fines, imprisonment, or professional disciplinary measures (entire instrument; see s 3; s 5; s 8-11).

Enforcement is administrative. The instrument’s enforcement mechanism is administrative decision‑making within the VEA and MRCA frameworks. Decision‑makers, using the SOP, will accept or reject claims based on whether the claimant proves the required factor(s) and the relationship to relevant service. The practical "sanction" for failing to satisfy the SOP is denial of a service‑connection finding and therefore denial or non‑entitlement to benefits that depend on service connection. The instrument itself contains no enforcement procedure; enforcement is effected by the usual administrative processes of DVA and MRCA claims handling (s 5; s 8; s 9; s 10).

Interaction with other legal enforcement mechanisms. Although the SOP contains no penalties, other laws and provisions within the VEA, MRCA, or general Commonwealth law may impose penalties for fraud, false statements, or misuse of benefits. Those provisions sit outside the SOP and are not altered by it. The SOP does, however, affect the evidentiary contours of entitlement decisions that may trigger other enforcement mechanisms; for example, a finding that a claim is not supported under the SOP could lead to administrative review and, where fraud is alleged, referral to appropriate investigative processes that operate under other statutory regimes.

Administrative review and oversight. Decisions made by DVA or other decision‑makers using the SOP can be subject to internal review, merits review mechanisms provided under the VEA or MRCA, and judicial review in appropriate circumstances. The SOP therefore operates within a wider enforcement ecology of administrative law remedies; those remedies are not set out in the SOP itself but are part of the statutory schemes to which it applies (s 5).

Practical enforcement issues. Because the SOP converts clinical concepts into legal thresholds, compliance is enforced through documentary evidence gathering, medical records checks, laboratory result verification, and expert medical opinion. Decision‑makers may require specific types of evidence that match the SOP’s definitions , for example quantified glucocorticoid dosing records, documented HbA1c or fasting glucose results, or water arsenic assays , and will treat absence of such evidence as a basis to find that the SOP’s factor is not established. The SOP therefore influences what evidence is requested and how decisions are justified.

Primary statutory framework. This SOP was made under the authority of subsection 196B(3) of the Veterans' Entitlements Act 1986 and applies to claims that fall under section 120B of the VEA or section 339 of the MRCA (s 3; s 5). Its legal effect is to guide the statutory decision‑makers who determine service connection under those Acts. The SOP is part of a network of legislative instruments the RMA issues under the VEA framework; it therefore functions as an interpretive and evidentiary adjunct to the VEA and MRCA claims processes.

Cross‑references to other Statements of Principles. Section 11 provides for direct interaction with other SOPs: where a factor in this SOP refers to an injury or disease that is the subject of another SOP, the factors in that other SOP apply in accordance with its terms. That creates a legal interdependence between SOPs; in practice decision‑makers must read this SOP in the context of any other SOPs implicated by its factors (s 11).

Relationship with clinical classifications. The SOP refers to ICD‑10‑AM codes E10-E14 but makes explicit that for the purposes of this instrument diabetes mellitus means what is set out in s 7(2) (s 7(3)-(4)). The instrument therefore uses ICD coding for cross‑reference but establishes its own statutory diagnostic definition. This means that clinical coding alone is not determinative; compliance requires meeting the instrument’s specific diagnostic thresholds.

Overlap with public health and occupational exposure regulation. The SOP’s arsenic exposure test requires evidence of drinking water with an average arsenic concentration or cumulative exposure equivalent to specified thresholds, or clinical evidence of chronic arsenic toxicity (Schedule 1). That creates a point of interface with environmental and public health data, such as water quality testing regimes; those regimes are governed by other laws and regulations, but their factual outputs may be used to satisfy the SOP’s criteria.

Interface with pharmaceutical regulatory regimes. The SOP lists many drugs in Specified List 1 and Specified List 2 and treats exposure to those drugs as factors for onset or worsening (Schedule 1; s 9(4), s 9(12)). While the SOP does not regulate prescribing, it creates legal significance for particular drug exposures. Pharmaceutical regulation, scheduling, and subsidy regimes remain governed by separate laws; the SOP uses drug names and classes as factual markers within its entitlement framework.

Administrative law and review frameworks. The SOP does not alter the existence of rights to internal review, merits review, or judicial review of administrative decisions under the VEA or MRCA. Decisions using this SOP therefore remain subject to the usual administrative law principles, including requirements for reasoned decision‑making, natural justice, and the availability of judicial review where appropriate. The instrument itself does not set those procedural rights; it provides the substantive test used in application of the relevant statutes.

Amendment and legislative context. The SOP is part of an evolving legislative instrument series; the endnotes record multiple amendments (Endnote 3 and Endnote 4). Amendments to the SOP interact with the VEA legislative environment and may change the legal thresholds that decision‑makers must apply, for example by adding or removing specified drugs or altering definitions such as one pack‑year. Practitioners must therefore consider both the SOP text and its amendment history when applying it to claims (Endnote 3; Endnote 4).

The compilation includes amendments up to Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022), which came into effect on 19 September 2022. The endnotes in the compiled instrument record the legislative history and the specific amendment events (Endnote 3; Endnote 4).

Key entries from the legislation history (Endnote 3):

• Statement of Principles concerning diabetes mellitus (No. 49 of 2020) , Registered 29 June 2020 (F2020L00822), commenced 27 July 2020.
• Amendment Statement of Principles concerning diabetes mellitus (No. 84 of 2021) , Registered 30 June 2021 (F2021L00927), commenced 26 July 2021.
• Amendment Statement of Principles concerning diabetes mellitus (No. 50 of 2022) , Registered 2 May 2022 (F2022L00666), commenced 30 May 2022.
• Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022) , Registered 26 August 2022 (F2022L01128), commenced 19 September 2022.

Specific provision‑level amendments are recorded in Endnote 4. Highlights, as recorded there, include:

• Section 2 and Section 4 were affected by repeal provisions of the Legislation Act (Endnote 4 indicates "Section 2 … rep LA s 48D" and "Section 4 … rep LA s 48C"). The compiled instrument reflects the text as amended to 19 September 2022.
• Subsection 9(6)(e) was amended by Amendment No. 84 of 2021 and later revised by No. 50 of 2022, indicating the immune checkpoint inhibitor or interferon entry for type 1 diabetes was added/adjusted during these amendment events. Endnote 4 lists "Subsection 9(6)(e) … rs No. 50 of 2022" and earlier "rs No. 84 of 2021".
• Subsection 9(13a) was added by No. 84 of 2021 and subsequently raised to a repealed/ substituted status by No. 50 of 2022 ("Subsection 9(13a) … ad No. 84 of 2021" and "Subsection 9(13a) … rs No. 50 of 2022"). The Schedule 1 definition of "immune checkpoint inhibitor" was also added by No. 50 of 2022 (Endnote 4).
• The definition of one pack‑year in Schedule 1 was amended by No. 94 of 2022, as noted in the amendment history entries for subsections 9(7)(a) and 9(21)(a) notes and the Schedule 1 dictionary line items ("Subsection 9(7)(a) note … rs No. 94 of 2022"; "Schedule 1 - Dictionary - one pack‑year … rs No. 94 of 2022").

The endnotes explain that the compilation includes amendments up to the compilation date and describes which amendments are in force. Practitioners should consult the Legislation Register for any uncommenced amendments or later changes that post‑date the compilation (compilation header and Endnote 3 commentary).

Practical consequence of the amendment record. The amendment history shows that the SOP is actively maintained and that specific medical exposures and definitions have been added or adjusted. Notable changes concern immune checkpoint inhibitors and interferons, and the definition of pack‑year; these are examples of evolving medical evidence or policy choices being reflected in the SOP. The recorded amendments specify where to look when assessing claims framed around those particular factors or definitions, and counsel and decision‑makers should ensure they use the version of the SOP that applied at the time relevant to the claim.

The compiled instrument and its endnotes do not record any case law or litigation history. The SOP itself lists no judicial decisions or tribunal determinations. Endnote 3 and Endnote 4 provide legislative and amendment history only; there is no litigation history entry in the instrument’s endnotes.

What this means in practice. The absence of litigation history in the instrument does not preclude the possibility that decisions applying this SOP have been subject to administrative review, merits review, or judicial review under the VEA or MRCA. However, the SOP as published contains no references to precedential court determinations, and the RMA’s expression in s 8 about what is "more probable than not" is an administrative medical‑scientific view, not a judicial finding.

How to proceed if litigation is anticipated. If a claimant or respondent anticipates administrative or judicial review in relation to a diabetes claim, practitioners should:

• Locate and review decisions by tribunals and courts that considered this SOP, the general legal test for service connection under the VEA and MRCA, or the evidentiary weight of specific factors (this instrument does not include those materials).
• Check public databases of administrative and judicial decisions, as well as merits review tribunals relevant to VEA/MRCA claims, for any reported determinations applying this SOP.
• Ensure that any evidence assembled maps closely to the SOP’s definitions, because tribunal or court scrutiny will focus on whether the decision‑maker correctly applied the SOP’s medical and temporal thresholds.

Because the instrument itself records no litigation, practitioners must rely on external research to locate case law or tribunal decisions that interpret or apply the SOP.

Relying on ICD codes alone is insufficient. The SOP notes that while diabetes mellitus attracts ICD‑10‑AM codes E10 to E14, the legal meaning for the SOP is what s 7(2) specifies (s 7(3)-(4)). Practitioners should not treat ICD coding as a substitute for the instrument’s diagnostic thresholds. The SOP requires either two positive laboratory tests on separate days meeting the numeric thresholds, or a qualifying episode of diabetic ketoacidosis or hyperosmolar hyperglycaemic state meeting a glucose threshold. Absence of those specific test results risks rejection of a claim even if a clinical diagnosis label is present in medical records (s 7(2)(a)(i)-(ii)).

Timing and temporal windows matter. Several factors include explicit timing requirements:

• Glucocorticoid therapy: where glucocorticoid therapy (as specified in Schedule 1) has ceased or decreased, the last dose must have been within 30 days before clinical onset or worsening (s 9(3); s 9(11); Schedule 1 definitions for "glucocorticoid therapy as specified").
• Immune checkpoint inhibitor or interferon exposure: must have occurred within one year before clinical onset or worsening for relevant subsections (s 9(6)(e); s 9(13a)).
• Smoking cessation: where smoking has permanently ceased, clinical onset or worsening must occur within 15 years of cessation for the smoking criteria to apply (s 9(7)(a); s 9(21)(a)).

If documentary evidence does not show precise dates or last exposure timing, the claimant may fail to demonstrate the required temporal nexus.

Differentiation between onset and worsening. The SOP separates factors that can establish causation for clinical onset from those that establish material contribution to or aggravation of pre‑existing diabetes (compare s 9(1)-(8) and s 9(9)-(23)). For a disease that pre‑existed service, only certain subsections apply and must be shown to have contributed materially or aggravated the condition while related to service (s 10(2)). Misclassifying a claim as an "onset" case when the disease pre‑existed service, or vice versa, can lead to incorrect application of the SOP.

Nuanced definitions converted to legal thresholds. The Schedule turns clinical measures into legal tests that may not match everyday clinical records. Examples:

• Overweight or obese is defined as BMI ≥ 25 or waist circumference > 80 cm in women or > 94 cm in men; the SOP requires this status for at least five years before onset or worsening (s 9(7)(c); s 9(21)(c); Schedule 1). Intermittent or poorly documented BMI records can create a dispute.
• Physical incapacity is framed as inability to undertake moderate activity of at least four METs for at least five years (s 9(7)(d); s 9(21)(d); Schedule 1 defines MET). This will require objective functional assessment or consistent clinical notes.
• Second‑hand smoke requires being in enclosed spaces inhaling smoke and a cumulative exposure threshold of 5,000 hours (s 9(7)(b); s 9(21)(b); Schedule 1). That is a high evidentiary bar.

Specified drug lists and the "cannot be ceased or substituted" phrase. Subsections 9(4) and 9(12) require treatment with a drug from Specified List 1 that "cannot be ceased or substituted" for specified periods before onset or worsening. The phrase "cannot be ceased or substituted" triggers factual inquiries about the clinical necessity for continued therapy; claimants must provide clinical justification and prescriber notes showing that cessation or substitution was not viable. Absence of such justification may undermine reliance on the listed drug as a factor (s 9(4); s 9(12); Schedule 1).

Glucocorticoid thresholds are exacting. The Schedule contains a table of equivalent glucocorticoid doses and precise cumulative and average dose requirements that must be met for glucocorticoid therapy to count (Schedule 1). Clinicians often abbreviate dosing records; without cumulative and averaged dose calculations tied to the Schedule thresholds, evidence may fall short.

Pack‑year calculation details were amended. The Schedule’s definition of one pack‑year was amended by a 2022 determination and includes equivalents in grams of tobacco and a conversion rule for pipe tobacco and cigars. Practitioners must use the current legal definition when calculating pack‑years for claims, because the SOP uses pack‑years as a trigger for type 2 diabetes criteria (s 9(7)(a); s 9(21)(a); Schedule 1; Endnote 3; Endnote 4).

Cross‑SOP dependency can complicate proof. Section 11 requires that where a factor refers to another SOP, the factors in that other SOP apply. This means a claimant relying on, for example, a specified endocrine disorder that itself is the subject of another SOP must ensure that evidence also satisfies that other SOP. Failure to account for cross‑references may result in overlooked requirements and unsuccessful claims (s 11).

"Inability to obtain appropriate clinical management" is vague in proof terms. Subsection 9(23) lists inability to obtain appropriate clinical management for diabetes as a factor. The SOP gives no specific evidentiary thresholds for what constitutes inability; claimants will need contemporaneous records of referrals, attempts to obtain care, waiting lists, geographic or service continuity barriers, or other documentary proof. The vagueness of this standard makes it a potential focus of dispute.

Death cases require causation of the terminal event. For deaths, the SOP includes death from a terminal event or condition "that was contributed to by" diabetes mellitus (s 7(5)). Proving that diabetes contributed to terminal events like pneumonia or cardiac arrest will often require expert evidence linking diabetic pathophysiology to the terminal event; simple presence of diabetes on a death certificate may be insufficient.

Map the claim to the SOP first. Before lodging or defending a claim, identify whether the claimant’s condition meets the SOP’s diagnostic criteria for diabetes mellitus (s 7(2)(a)(i)-(ii)). Obtain laboratory reports showing the required fasting plasma glucose, 2‑hour glucose tolerance test results, or HbA1c values on two separate days where required, or documentation of a qualifying metabolic decompensation event with blood glucose ≥ 11.1 mmol/L (s 7(2)). For death claims, compile medical records and, if available, an expert opinion linking diabetes to the terminal event (s 7(5)).

Assemble time‑mapped medical evidence. The SOP is time‑sensitive. Produce a timeline that links the clinical onset or clinical worsening of diabetes to the claimed factor and to relevant service. For factors that require a last dose window, such as glucocorticoids within 30 days, show prescription and administration dates, cumulative doses, and documentation of cessation or reduction (s 9(3); s 9(11); Schedule 1). For immune checkpoint inhibitors or interferons, show dates of administration within the one‑year window (s 9(6)(e); s 9(13a)).

Document medication exposure precisely. If relying on drug exposure under Specified List 1 or Specified List 2, compile complete medication histories, including dates, doses, routes of administration, whether therapy could be ceased or substituted with alternatives, and prescriber rationale. For glucocorticoids, calculate cumulative dose and average dose per day against the Schedule 1 table of equivalents and confirm whether inhaled, ocular, nasal, topical, or concurrent Specified List 2 drug use meet the "glucocorticoid therapy as specified" definition (Schedule 1; s 9(3); s 9(11)).

Prove lifestyle and exposure factors with contemporaneous records. For smoking history, compute pack‑years using the Schedule 1 formula and provide contemporaneous notes showing cigarettes per day and cessation date; for second‑hand smoke, assemble statements, employment records, or exposure logs estimating hours in enclosed spaces to meet the 5,000 hour threshold (s 9(7)(a)-(b); s 9(21)(a)-(b); Schedule 1). For overweight/obesity, gather repeated BMI measurements or waist circumference records over a five‑year period prior to onset or worsening (s 9(7)(c); s 9(21)(c); Schedule 1).

Establish functional capacity evidence. For the METs requirement, obtain objective functional assessments or repeated clinician notes indicating inability to perform activities at or above 4 METs for at least five years (s 9(7)(d); s 9(21)(d); Schedule 1). Where objective testing such as exercise testing is not available, detailed clinical notes from treating practitioners explaining limitations and functional capability will be needed.

Collect disease‑specific and specialist evidence. For pancreatic surgery, pathological pancreatic conditions, haemolytic uraemic syndrome, transplants, HIV/HCV infection, cirrhosis, non‑alcoholic steatohepatitis, psychiatric disorders, bilateral orchiectomy, anti‑androgen therapy, or ingestion of specific toxins like Vacor, obtain specialist reports, operative notes, pathology results, diagnostic imaging, serology, and hospital discharge summaries that document the condition and its timing relative to onset/worsening (s 9(2); s 9(6)(a)-(c); s 9(7)(e)-(k); s 9(14)-(17); Schedule 1).

Address "inability to obtain appropriate clinical management". For reliance on s 9(23), assemble contemporaneous evidence showing attempts to obtain care (referrals, appointment booking records), documented barriers (service unavailability, geographic isolation, system or administrative denial), and any correspondence with health providers or authorities. A considered narrative plus documentary proof will be needed because the SOP offers no prescriptive threshold for this factor.

Confirm linkage to relevant service. For each factor relied upon, show how that factor is related to the claimant’s relevant service as defined in Schedule 1. This will require evidence that the exposure, treatment, or event occurred during service or followed from service activities, or that the relevant service caused or materially contributed to the factor (s 10(1)-(2); Schedule 1 definition of relevant service). For example, medication administered in the course of service should be supported by service medical records and dosing logs.

Cross‑check other SOPs where necessary. If a claimed factor refers to another SOP under s 11, obtain and apply the current text of that other SOP and compile evidence that satisfies both instruments where applicable. This reduces the risk of missing a cross‑referenced requirement.

Use expert opinion strategically. For complex causal links, particularly where the SOP requires a contribution to a terminal event, or where the clinical evidence is equivocal, obtain focused expert medical opinions that map directly to the SOP criteria. Experts should be instructed to address whether the SOP factors are met on the balance of probabilities and to explain the temporal and mechanistic link between the factor, the claimant’s service, and the onset or worsening of diabetes.

Stay current with amendments. The SOP has been amended since its original registration in 2020. Practitioners must ensure they apply the version of the SOP that is legally operative at the relevant time for the claim. Check the Legislation Register for uncommenced or more recent amendments beyond the compilation date, and note the amendment history entries in the instrument’s endnotes (Endnote 3; Endnote 4).

Prepare reasonable witness statements and corroborating material. Non‑medical evidence can be important: statements from unit medical officers, other service personnel confirming exposure or treatments, workplace logs, water quality testing for arsenic exposure, and contemporaneous civilian medical notes. Where objective metrics are absent, corroborative documentary evidence can support credibility and fill evidentiary gaps.

Structure submissions to decision‑makers. When presenting a claim or response, set out a clear table or timeline that aligns each piece of evidence with the specific SOP subsection it is intended to satisfy. Explicitly state the diagnostic criteria met under s 7(2), list the factor(s) in s 9 relied upon, explain how each is related to relevant service under s 10(1), and reference any cross‑applied SOPs per s 11. This mapping reduces the risk of misapplication by decision‑makers and clarifies the precise legal‑medical questions for review.